The Oley Foundation
The Oley Foundation is a national non-profit organization, founded in 1983. They aim to “enrich the lives of patients dependent on home intravenous nutrition (parenteral) and tube feeding (enteral) through education, advocacy, and networking.” They are a “resource for consumer’s families, clinicians and industry representatives, and other interested parties. The Foundation gives members the tools and confidence they need to manage their complex therapy and enables them to achieve normalcy in their lives.”
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Gastroschisis, Short bowel syndrome, Systemic Scleroderma, Gastroparesis
For People with Gastroparesis, Holidays Can Be Painful
By Rachel Whetstone from In The Cloud Copy Food is fundamentally linked with celebrations in every culture around the world. Families gather for a feast
Gastroparesis Symptoms Significantly Improved via Gastric Electrical Stimulation
Gastric electrical stimulation (GES) has long been suggested as a treatment for symptoms of gastroparesis, but the use of the technique has been deemed
Phase 1 Study of Experimental Systemic Sclerosis Treatment Bermekimab Begins
According to a recent press release from XBiotech, a Texas-based biotechnology company, patient dosing is now underway in a phase 1 clinical study of the
Findings From a Mouse Study Could Have Major Implications for Scleroderma
According to a story from Scleroderma News, the results of a recent mouse study could have significant implications for the future of scleroderma treatment. In
ICYMI: New Treatment for Scleroderma Lung Disease Approved by the FDA
According to a story from American Nurse Today, the US Food and Drug Administration (FDA) approved a treatment on September 6th, 2019 for interstitial lung
First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
According to a story from Financial Buzz, the drug developer Emerald Health Pharmaceuticals, Inc., recently announced that the company had completed a phase 1 clinical
